The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients

被引：0
|
作者：
Elisabetta Munzone
Alessandra Fabi
Giuseppe Buono
Roberta Caputo
Emilia Montagna
Mara Negri
Francesco Nuzzo
Antonella Palazzo
Ida Paris
Luca Conti
Anna Baggi
Jean Marie Franzini
Michelino De Laurentiis
机构：
[1] Istituto Europeo di Oncologia,Precision Medicine Unit in Senology
[2] IRCCS,Medical Oncology Unit Fondazione
[3] Fondazione Policlinico Universitario Agostino Gemelli,Ginaecological Oncology Unit Fondazione
[4] National Cancer Institute “Fondazione Pascale”,Life Sciences Division
[5] Policlinico Universitario Agostino Gemelli,undefined
[6] Policlinico Universitario Agostino Gemelli,undefined
[7] Business Integration Partners,undefined
来源：
Drugs & Therapy Perspectives | 2023年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：432 / 446
页数：14
相关论文
共 50 条
  • [31] BUDGET IMPACT AND COST MINIMIZATION ANALYSIS OF PHESGO ® (TRASTUZUMAB plus PERTUZUMAB SC) FOR THE TREATMENT OF HER2+BREAST CANCER IN THE CHILEAN PUBLIC HEALTH SYSTEM
    Rojas, R.
    Velasquez, M.
    Jana, N.
    Arriagada, L.
    Arenillas, S.
    Esquivel, C.
    Mendoza, C.
    Gejman, C.
    VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
  • [32] Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Crnjevic, Tanja Badovinac
    Jackisch, Christian
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Hogea, Alexandra
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Jackisch, Christian
    LANCET ONCOLOGY, 2021, 22 (01): : 85 - 97
  • [34] Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer
    De Sanctis, R.
    D'Antonio, F.
    Agostinetto, E.
    Marinello, A.
    Masci, G.
    Zuradelli, M.
    Losurdo, A.
    Guiducci, D.
    Tinterri, C.
    Testori, A.
    Gatzemeier, W.
    Errico, V.
    Torrisi, R.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 71 - 71
  • [35] COST COMPARISON BETWEEN THE USE OF PERTUZUMAB-TRASTUZUMAB SC AND IV FORMULATIONS TO TREAT HER2+BREAST CANCER PATIENTS IN ALGERIA
    Hedibel, M.
    Bouchebout, H. A.
    Ghomari, I
    Al Assaad, A.
    Guendouzi, S.
    VALUE IN HEALTH, 2024, 27 (12) : S111 - S111
  • [36] Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study
    Wong, Chi Yan
    Leung, Roland
    Kwok, Gin Wai
    Tsang, Josephine
    Li, Bryan
    Yau, Thomas
    Chiu, Joanne
    POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1163) : 666 - 669
  • [37] A phase Ib dose-finding study of subcutaneous pertuzumab in combination with subcutaneous trastuzumab in healthy male volunteers and female patients with early breast cancer
    Kirschbrown, Whitney P.
    Wynne, Chris
    Kagedal, Matts
    Wada, Russ
    Li, Hanbin
    Nijem, Ihsan
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Eng-Wong, Jennifer
    Garg, Amit
    CANCER RESEARCH, 2018, 78 (04)
  • [38] ANALYSIS OF NON-PHARMACOLOGICAL COST SAVINGS DERIVED FROM THE USE OF FIXED- DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN PATIENTS WITH HER2POSITIVE BREAST CANCER IN SPAIN
    Calleja, T.
    Galve-Calvo, E.
    Gomez Agudo, E.
    Llaguno, J. L.
    Martin Rufo, M.
    Arroyo, I
    Lagunar Ruiz, J.
    Lores, M.
    Monzon, M.
    Saura, C.
    VALUE IN HEALTH, 2023, 26 (12) : S153 - S153
  • [39] Population pharmacokinetic (PK) analysis of trastuzumab confirms the appropriateness of a fixed (non-weight-based) subcutaneous (SC) formulation dose in patients with HER2-positive early breast cancer (EBC)
    Quartino, A.
    Li, J.
    Li, H.
    Wada, D. R.
    Visich, J.
    Li, C.
    Jin, J. Y.
    Lum, B.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S44 - S44
  • [40] A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) plus relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO plus RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma
    Liu, Steven Y.
    Babadjanova, Zulfia
    Oyetunde, Ijeoma
    Gurm, Balmeet
    Jiang, Ruiyun
    Lord-Bessen, Jennifer
    Dixon, Matthew
    Sanchez, Teresa Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345